| 초록 |
Eye drop formulation for glaucoma drug is limited in very short drug residence time at the preocular space, hence very low drug bioavailability. To resolve this, we proposed PEG-coated mesoporous silica as carriers of a glaucoma drug, brimonidine. The amine-functionalized mesoporous silica was fabricated via anionic surfactant-mediated synthesis method (S-N+~I- mechanism), which were coated with PEG (M.W. 6000) to allow a mucoadhesive effect. We evaluated their in vitro drug release profile in pH 7.4 PBS. After a burst release of 33% on the first 20 min, the drug was slowly released for 8 hours. In vivo experiments were conducted with the PEG-coated AMS, where after their topical application to the rabbit eye, we measured the change in intraocular pressure to examine the efficacy of brimonidine. Our findings showed that the period of lowered IOP was about 14 h after the administration, which is more than twice longer than that with a commercial brimonidine eye drop, Alphagan P (6 h). |
